A Phase 1/2 interventional study of Zanubrutinib in B-cell Malignancies, sponsored by BeiGene. Completed at 23 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-28.
Sponsored by BeiGene · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluated the safety, tolerability, pharmacokinetic profile and efficacy of BGB-3111 in participants with B-cell lymphoid malignancies.
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered up to 320 mg total daily dose of zanubrutinib until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up
Drug: Zanubrutinib
Oral administration by capsule
Also known as: BGB-3111, Brukinsa
Part 1 and Part 2: Number of Participants With Adverse Events
Number of participants with adverse events and serious adverse events, including clinically relevant physical examinations and laboratory measurements
Time frame: Up to approximately 6 years and 7 months
Part 1: Recommended Phase 2 Dose (RP2D) for Zanubrutinib
RP2D for zanubrutinib was the maximum tolerated dose (MTD) or less, which was determined by testing increasing doses up to 320 mg QD
Time frame: Month 9
Part 1 and Part 2: Area Under the Curve From Time 0 to the Last Sampling Time Point Within the Dose Interval (AUClast) of Zanubrutinib
Time frame: Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Part 1 and Part 2: Area Under the Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Zanubrutinib
Time frame: Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Part 1 and Part 2: Maximum Observed Plasma Concentration (Cmax) After Administration of Zanubrutinib
Time frame: Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Part 1 and Part 2: Maximum Observed Plasma Concentration (Cmax) After Administration of Zanubrutinib
Time frame: Week 2 Day 1 pre-dose and 24 hours
Part 1 and Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib
Time frame: Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Part 1 and Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib
Time frame: Week 2 Day 1 pre-dose and 24 hours
Part 1 and Part 2: Apparent Terminal Half-life (t1/2) of Zanubrutinib
Time frame: Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Part 1 and Part 2: Apparent Clearance (CL/F) of Zanubrutinib
Time frame: Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Part 1 and Part 2: Apparent Volume of Distribution of Zanubrutinib During the Terminal Phase (Vz/F)
Time frame: Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Part 1 and Part 2: Overall Response Rate (ORR)
ORR is defined as the percentage of participants with partial or complete response (CR), as assessed by the investigator. For CLL/SLL, ORR includes partial response (PR) with lymphocytosis (PR-L) or better (includes PR-L, PR, nodular PR or nPR and CR with incomplete marrow recovery or CRi) and for MW, ORR includes minor response or better. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).
Time frame: Up to 6 years and 7 months
Part 1 and Part 2: Complete Response Rate (CRR)
CRR is defined as the percentage of participants who achieve a complete response, as assessed by the investigator. For CLL/SLL, CRR includes CRi or better. For WM, CRR includes very good partial response (VGPR) or better. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).
Time frame: Up to 6 years and 7 months
Part 1 and Part 2: Partial Response (PR) or Better
PR or better is defined as the percentage of participants who achieve a partial response or better, as assessed by the investigator. For CLL/SLL, includes PR, nPR, CRi, CR and for WM includes PR, VGPR, and CR. Efficacy results are reported for the B-cell malignancy subtypes chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Waldenström macroglobulinemia (WM).
Time frame: Up to 6 years and 7 months
Part 1 and Part 2: Progression-free Survival (PFS)
PFS is defined as the time from the first dose date of study drug to the date of the earliest occurrence of progressive disease or death due to any cause, whichever occurs first. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).
Time frame: Up to 6 years and 7 months
Part 1 and Part 2: Overall Survival (OS)
OS is defined as the time from the date of the first dose to death due to any cause. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).
Time frame: Up to 6 years and 7 months
Part 1 and Part 2: Duration of Response (DOR)
DOR for responders is defined as time from the date of the earliest qualifying response to the date of progressive disease or death for any cause, whichever occurs earlier. Efficacy results are reported for responders (defined as PR or better, except CLL/SLL and WM) in each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; PR with lymphocytosis or better), Waldenstrom macroglobulinemia (WM; minor response or better), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).
Time frame: Up to 6 years and 7 months
Number of Participants With Greater Than 75% Bruton's Tyrosine Kinase (BTK) Occupancy
Number of participants with greater than 75% BTK occupancy of zanubrutinib in peripheral blood mononuclear cells (PBMCs)
Time frame: Week 1 Day 1 (W1D1) predose, W1D1 4 hours, W1D2 24 hours, W1D3 predose, and W2D1 predose
The study was conducted in 2 parts. The dose escalation part (Part 1) determined the recommended phase 2 dose (RP2D) and regimen and the dose expansion part (Part 2) further characterized the safety and efficacy at the RP2D.
| Milestone | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD |
|---|---|---|---|---|---|
| Started | 3 | 4 | 5 | 4 | 1 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 4 | 5 | 4 | 1 |
| Withdrew: Sponsor decision | 1 | 2 | 3 | 2 | 0 |
| Withdrew: Death | 1 | 2 | 2 | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 274 | 94 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 274 | 94 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 165 | 67 |
| Withdrew: Death | 0 | 0 | 0 | 74 | 17 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 28 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 5 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 1 |
Number of participants with adverse events and serious adverse events, including clinically relevant physical examinations and laboratory measurements
| Participants | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Parts 1 and 2: 160 mg BID | Parts 1 and 2: 320 mg QD |
|---|---|---|---|---|---|
| At least one treatment-emergent adverse event | 3 | 4 | 5 | 274 | 94 |
| Serious adverse events | 1 | 2 | 3 | 157 | 45 |
RP2D for zanubrutinib was the maximum tolerated dose (MTD) or less, which was determined by testing increasing doses up to 320 mg QD
| milligrams | Part 1: Zanubrutinib |
|---|---|
| Part 1: Recommended Phase 2 Dose (RP2D) for Zanubrutinib | 320 |
| nanograms/milliliters*hour | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Parts 1 and 2: 160 mg BID | Parts 1 and 2: 320 mg QD |
|---|---|---|---|---|---|
| Part 1 and Part 2: Area Under the Curve From Time 0 to the Last Sampling Time Point Within the Dose Interval (AUClast) of Zanubrutinib | 274.7 ± 47.8 | 436.8 ± 103.5 | 1480 ± 53.0 | 1132 ± 61.1 | 2281 ± 60.5 |
| nanograms/milliliters*hour | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD |
|---|---|---|---|---|---|
| Part 1 and Part 2: Area Under the Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Zanubrutinib | 301.1 ± 51.5 | 460.0 ± 100.6 | 1505 ± 52.7 | 1253 ± 59.0 | 2538 ± 47.8 |
| nanograms/milliliter | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD |
|---|---|---|---|---|---|
| Part 1 and Part 2: Maximum Observed Plasma Concentration (Cmax) After Administration of Zanubrutinib | 86.0 ± 46.6 | 125 ± 77.6 | 397 ± 76.1 | 304 ± 63.8 | 566 ± 65.6 |
| nanograms/milliliter | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD |
|---|---|---|---|---|---|
| Part 1 and Part 2: Maximum Observed Plasma Concentration (Cmax) After Administration of Zanubrutinib | 75.7 ± 36.2 | 169 ± 50.0 | 387 ± 60.7 | 299 ± 56.1 | 533 ± 55.0 |
| Hours | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD |
|---|---|---|---|---|---|
| Part 1 and Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib | 1.00 (0.50 to 1.98) | 2.00 (1.17 to 2.00) | 1.92 (0.93 to 2.08) | 2.00 (0.83 to 8.00) | 2.00 (0.72 to 3.08) |
| Hours | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD |
|---|---|---|---|---|---|
| Part 1 and Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib | 2.00 (2.00 to 2.00) | 2.50 (1.08 to 3.00) | 2.00 (1.00 to 3.17) | 2.00 (0.53 to 6.00) | 2.00 (0.33 to 6.00) |
| Hours | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD |
|---|---|---|---|---|---|
| Part 1 and Part 2: Apparent Terminal Half-life (t1/2) of Zanubrutinib | 1.94 ± 28.5 | 1.97 ± 29.8 | 3.87 ± 24.9 | 2.73 ± 60.2 | 3.30 ± 61.2 |
| Liters/hour | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD |
|---|---|---|---|---|---|
| Part 1 and Part 2: Apparent Clearance (CL/F) of Zanubrutinib | 133 ± 51.5 | 174 ± 100.6 | 106 ± 52.7 | 128 ± 59.4 | 126 ± 47.8 |
| Liters | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD |
|---|---|---|---|---|---|
| Part 1 and Part 2: Apparent Volume of Distribution of Zanubrutinib During the Terminal Phase (Vz/F) | 371 ± 47.5 | 494 ± 78.9 | 593 ± 61.6 | 530 ± 70.0 | 600 ± 97.6 |
ORR is defined as the percentage of participants with partial or complete response (CR), as assessed by the investigator. For CLL/SLL, ORR includes partial response (PR) with lymphocytosis (PR-L) or better (includes PR-L, PR, nodular PR or nPR and CR with incomplete marrow recovery or CRi) and for MW, ORR includes minor response or better. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).
| Percentage of participants | Part 1 and Part 2: Overall |
|---|---|
| CLL/SLL | 95.2 (89.8 to 98.2) |
| WM | 95.9 (88.5 to 99.1) |
| MCL | 82.5 (70.1 to 91.3) |
| MZL | 85.0 (62.1 to 96.8) |
| FL | 36.4 (20.4 to 54.9) |
| DLBCL | 42.2 (27.7 to 57.8) |
| RT | 61.5 (31.6 to 86.1) |
| HCL | 58.3 (27.7 to 84.8) |
CRR is defined as the percentage of participants who achieve a complete response, as assessed by the investigator. For CLL/SLL, CRR includes CRi or better. For WM, CRR includes very good partial response (VGPR) or better. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).
| Percentage of participants | Part 1 and Part 2: Overall |
|---|---|
| CLL/SLL | 16.8 (10.7 to 24.5) |
| WM | 46.6 (34.8 to 58.6) |
| MCL | 28.1 (17.0 to 41.5) |
| MZL | 20.0 (5.7 to 43.7) |
| FL | 18.2 (7.0 to 35.5) |
| DLBCL | 24.4 (12.9 to 39.5) |
| RT | 15.4 (1.9 to 45.4) |
| HCL | 16.7 (2.1 to 48.4) |
PR or better is defined as the percentage of participants who achieve a partial response or better, as assessed by the investigator. For CLL/SLL, includes PR, nPR, CRi, CR and for WM includes PR, VGPR, and CR. Efficacy results are reported for the B-cell malignancy subtypes chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Waldenström macroglobulinemia (WM).
| Percentage of participants | Part 1 and Part 2: Overall |
|---|---|
| CLL/SLL | 92.0 (85.8 to 96.1) |
| WM | 82.2 (71.5 to 90.2) |
PFS is defined as the time from the first dose date of study drug to the date of the earliest occurrence of progressive disease or death due to any cause, whichever occurs first. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).
| Months | Part 1 and Part 2: Overall |
|---|---|
| CLL/SLL | 61.4 (55.2 to NA) |
| WM | NA (48.9 to NA) |
| MCL | 27.6 (15.4 to 45.5) |
| MZL | NA (17.1 to NA) |
| FL | 10.4 (7.7 to 22.9) |
| DLBCL | 4.1 (2.1 to 5.6) |
| RT | 17.3 (2.8 to NA) |
| HCL | NA (28.7 to NA) |
OS is defined as the time from the date of the first dose to death due to any cause. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).
| Months | Part 1 and Part 2: Overall |
|---|---|
| CLL/SLL | NA (NA to NA) |
| WM | NA (NA to NA) |
| MCL | NA (27.2 to NA) |
| MZL | NA (NA to NA) |
| FL | NA (37.3 to NA) |
| DLBCL | 14.7 (5.5 to 24.8) |
| RT | 29.3 (4.2 to NA) |
| HCL | NA (26.6 to NA) |
DOR for responders is defined as time from the date of the earliest qualifying response to the date of progressive disease or death for any cause, whichever occurs earlier. Efficacy results are reported for responders (defined as PR or better, except CLL/SLL and WM) in each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; PR with lymphocytosis or better), Waldenstrom macroglobulinemia (WM; minor response or better), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).
| Months | Part 1 and Part 2: Overall |
|---|---|
| CLL/SLL | 58.6 (52.6 to NA) |
| WM | NA (31.34 to NA) |
| MCL | 28.2 (16.2 to NA) |
| MZL | NA (6.5 to NA) |
| FL | NA (8.3 to NA) |
| DLBCL | 14.2 (2.8 to 26.2) |
| RT | 25.9 (5.9 to NA) |
| HCL | NA (NA to NA) |
Number of participants with greater than 75% BTK occupancy of zanubrutinib in peripheral blood mononuclear cells (PBMCs)
| Participants | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD |
|---|---|---|---|---|---|
| Number of Participants With Greater Than 75% Bruton's Tyrosine Kinase (BTK) Occupancy | 3 | 4 | 5 | 20 | 9 |
Collected over Up to 6 years and 7 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: 40 mg QD | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 1: 80 mg QD | 2/4 (50%) | 2/4 (50%) | 4/4 (100%) |
| Part 1: 160 mg QD | 2/5 (40%) | 3/5 (60%) | 5/5 (100%) |
| Part 1 and Part 2: 160 mg BID | 76/278 (27.3%) | 157/278 (56.5%) | 273/278 (98.2%) |
| Part 1 and Part 2: 320 mg QD | 19/95 (20%) | 45/95 (47.4%) | 94/95 (98.9%) |
| Event | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD |
|---|---|---|---|---|---|
| Abdominal sepsisInfections and infestations | 1/3 | 0/4 | 0/5 | 0/278 | 0/95 |
| Complicated appendicitisInfections and infestations | 1/3 | 0/4 | 0/5 | 0/278 | 0/95 |
| HeadacheNervous system disorders | 1/3 | 0/4 | 0/5 | 0/278 | 0/95 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/3 | 0/4 | 0/5 | 3/278 | 1/95 |
| CellulitisInfections and infestations | 0/3 | 1/4 | 0/5 | 9/278 | 3/95 |
| Renal artery thrombosisRenal and urinary disorders | 0/3 | 1/4 | 0/5 | 0/278 | 0/95 |
| PyrexiaGeneral disorders | 0/3 | 0/4 | 1/5 | 9/278 | 3/95 |
| Lower respiratory tract infectionInfections and infestations | 0/3 | 0/4 | 1/5 | 3/278 | 0/95 |
| PneumoniaInfections and infestations | 0/3 | 0/4 | 1/5 | 26/278 | 6/95 |
| Lentigo malignaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/4 | 1/5 | 0/278 | 0/95 |
| Event | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD |
|---|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 3/4 | 0/5 | 34/278 | 23/95 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 2/4 | 0/5 | 77/278 | 23/95 |
| Upper respiratory tract infectionInfections and infestations | 2/3 | 2/4 | 2/5 | 106/278 | 46/95 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/3 | 1/4 | 0/5 | 79/278 | 21/95 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 1/4 | 3/5 | 39/278 | 8/95 |
| NauseaGastrointestinal disorders | 1/3 | 2/4 | 1/5 | 45/278 | 18/95 |
| VomitingGastrointestinal disorders | 1/3 | 2/4 | 0/5 | 29/278 | 6/95 |
| PyrexiaGeneral disorders | 1/3 | 2/4 | 0/5 | 36/278 | 5/95 |
| HeadacheNervous system disorders | 0/3 | 2/4 | 2/5 | 46/278 | 18/95 |
| ContusionInjury, poisoning and procedural complications | 1/3 | 1/4 | 2/5 | 97/278 | 39/95 |
The Safety Analysis Set included all participants who received ≥ 1 dose of study drug
| Age, Continuous(Years) | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD | Total |
|---|---|---|---|---|---|---|
| Mean | 62.7 ± 9.45 | 62.3 ± 14.38 | 72.6 ± 8.88 | 66.4 ± 11.21 | 65.8 ± 11.24 | 66.3 ± 11.19 |
| Sex: Female, Male(Participants) | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 1 | 1 | 86 | 20 | 109 |
| Male | 2 | 3 | 4 | 192 | 75 | 276 |
| Race/Ethnicity, Customized(Participants) | Part 1: 40 mg QD | Part 1: 80 mg QD | Part 1: 160 mg QD | Part 1 and Part 2: 160 mg BID | Part 1 and Part 2: 320 mg QD | Total |
|---|---|---|---|---|---|---|
| White | 2 | 4 | 5 | 205 | 87 | 303 |
| Asian | 1 | 0 | 0 | 47 | 5 | 53 |
| Black or African American | 0 | 0 | 0 | 4 | 1 | 5 |
| Native Hawaiians or other Pacific Islanders | 0 | 0 | 0 | 2 | 0 | 2 |
| Multiple | 0 | 0 | 0 | 1 | 0 | 1 |
| Not Reported | 0 | 0 | 0 | 1 | 0 | 1 |
| Other | 0 | 0 | 0 | 18 | 2 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2014 to primary completion in Mar 2021, 78 months.
Results were first posted in Apr 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zanubrutinib